Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1993 1
1995 1
1998 1
2000 1
2001 1
2002 2
2003 1
2004 6
2005 1
2006 1
2007 2
2008 1
2009 2
2010 4
2011 5
2012 8
2013 14
2014 12
2015 8
2016 18
2017 20
2018 22
2019 15
2020 28
2021 38
2022 20
2023 19
2024 27
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. Among authors: alva a. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. Among authors: alva a. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Motzer RJ, et al. Among authors: alva a. J Natl Compr Canc Netw. 2022 Jan;20(1):71-90. doi: 10.6004/jnccn.2022.0001. J Natl Compr Canc Netw. 2022. PMID: 34991070 Free PMC article.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Among authors: alva a. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Yu J, et al. Among authors: alva a. Nat Med. 2021 Jan;27(1):152-164. doi: 10.1038/s41591-020-1131-x. Epub 2021 Jan 4. Nat Med. 2021. PMID: 33398162 Free PMC article.
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy.
Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R, Schaefer G, Allen SG, Sankar K, Fecher LA, Mendiratta-Lala M, Frankel TL, Qin A, Waninger JJ, Tezel A, Alva A, Lao CD, Ramnath N, Cieslik M, Harms PW, Green MD, Chinnaiyan AM, Zou W. Li G, et al. Among authors: alva a. Cancer Cell. 2023 Feb 13;41(2):304-322.e7. doi: 10.1016/j.ccell.2022.12.008. Epub 2023 Jan 12. Cancer Cell. 2023. PMID: 36638784 Free PMC article.
Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.
Zhang Y, Narayanan SP, Mannan R, Raskind G, Wang X, Vats P, Su F, Hosseini N, Cao X, Kumar-Sinha C, Ellison SJ, Giordano TJ, Morgan TM, Pitchiaya S, Alva A, Mehra R, Cieslik M, Dhanasekaran SM, Chinnaiyan AM. Zhang Y, et al. Among authors: alva a. Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):e2103240118. doi: 10.1073/pnas.2103240118. Proc Natl Acad Sci U S A. 2021. PMID: 34099557 Free PMC article.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. Motzer RJ, et al. Among authors: alva a. J Natl Compr Canc Netw. 2024 Feb;22(1):4-16. doi: 10.6004/jnccn.2024.0008. J Natl Compr Canc Netw. 2024. PMID: 38394781
Integrative clinical genomics of metastatic cancer.
Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieślik M, Chinnaiyan AM. Robinson DR, et al. Among authors: alva a. Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2. Nature. 2017. PMID: 28783718 Free PMC article.
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance.
Lin H, Kryczek I, Li S, Green MD, Ali A, Hamasha R, Wei S, Vatan L, Szeliga W, Grove S, Li X, Li J, Wang W, Yan Y, Choi JE, Li G, Bian Y, Xu Y, Zhou J, Yu J, Xia H, Wang W, Alva A, Chinnaiyan AM, Cieslik M, Zou W. Lin H, et al. Among authors: alva a. Cancer Cell. 2021 Apr 12;39(4):480-493.e6. doi: 10.1016/j.ccell.2020.12.023. Epub 2021 Jan 28. Cancer Cell. 2021. PMID: 33513345 Free PMC article.
240 results